Pharma & Life Sciences
Better decisions behind every medicine.
Connect your sales, price, trade and distribution data to ATC and EphMRA market class — then forecast, simulate and decide, with every source, assumption and range on the page.
Asked: where is the next growth in C10A?
Why
- Class volume +2.1%. Hospital demand is growing 2.1× faster than retail.
- Our hospital coverage sits 11 points below our retail coverage in Markets B and C.
- Trade terms leave 69% of the gross price move on the table.
Prepared for review — RGM lead
Read in pharma’s own structure
Group, filter, forecast and simulate on any of these without a mapping project.
- ATC 1–4
- EphMRA 1–4
- Molecule / API
- Rx / OTC
- Generic / Brand
- Dosage
- Channel retail · hospital · tender
- Market
The commercial decisions
Grow the portfolio. Improve speed to market.
Four forces move a portfolio’s value. Molsaro measures each one separately, so the next move goes where the growth actually is.
Where is the class growing fastest?
Demand by channel, indexed and held apart.
Which channel are we under-covered in?
Our coverage against where the class is growing.
What does a price move keep after trade terms?
Gross to net, per market, with the deductions named.
How much sooner can the next launch reach its markets?
Sequence, supply and channel readiness, modelled together.
Forecast
The best forecast is the one you can still change.
- A per-series model tournament picks the method, series by series — not one method imposed across the portfolio.
- Brand-level forecasts disaggregate to SKU and reconcile, so the parts and the whole agree.
- Every forecast carries its interval. A range stays a range.
- Change an assumption and it re-runs against the accepted plan while you are still in the room.
What the decision was worth
Measured against the plan you didn’t run.
- Every scenario names its reference case — the accepted plan, the forecast baseline, or the current strategy.
- Gross sales, trade spend, other deductions and net sales are measured, not estimated.
- Price, volume and mix are separated, so a revenue change has an explanation and not just a direction.
- Change a price, a term or a channel mix and the whole waterfall re-runs against the same reference case.
Gross to net on the recommended plan for C10A across four markets, compared with the accepted plan
- Gross sales EUR 128.4m
- Trade spend −EUR 31.6m
- Other deductions −EUR 8.2m
- Net sales EUR 88.6m
- Against the accepted plan +EUR 6.4m
- Gross-to-net
- 0.690
- Price
- +2.1
- Volume
- +3.6
- Mix
- −0.4
- Net
- +5.3
Specialist agents
Focus on decision-making, not reporting.
Four specialists come with the platform, work in your market class, and hand the finished work to a named person who signs it off.
Specialist agent commissions and one prepared result
| Specialist | Assigned | State |
|---|---|---|
| Molecule Performance Analyst | C10A share watch | Running |
| Patent & LOE Analyst | 2027 transitions | Running |
| EphMRA/ATC Market Class Analyst | C10A vs C10B | Prepared |
| Pharma Competitive Intelligence | 4 markets | Running |
Prepared for review
C10A grew 2.1%. Hospital is growing twice as fast as retail and we cover it least. Closing that gap is worth EUR 6.4m.
How the answer holds up
Commercial AI that shows its work.
Every answer is reproducible and auditable.
- A question resolves into named definitions before it touches data — “our class” becomes the EphMRA codes you registered.
- Each claim carries the system it came from and the period it was read.
- Ranges stay ranges. A modelled value is shown with its interval, never as a single confident number.
- Row-level security means a market lead sees their markets, and the answer changes with the person asking.
- Nothing is adopted into a plan until a named owner accepts it.
Where is the next growth in C10A, and what is it worth?
Method — 3 registered definitions, 3 systems, 9 periods
-
Hospital demand in C10A grew 2.1× faster than retail across the last four periods.
Snowflake · sell-in, P01–P09
-
Our hospital coverage is 11 points below our retail coverage in Markets B and C.
SAP S/4HANA · trade terms, P09
-
The class map places both markets in EphMRA C10A, not C10B.
EphMRA class map · v2026.1
-
Closing the coverage gap is worth EUR 6.4m net revenue, within a range of EUR 4.8m to EUR 7.9m.
Scenario · vs accepted plan, 4 markets
What Molsaro reads
Build one source of truth for your enterprise.
Everything Molsaro reads, converging on one governed model
Systems we connect to
- Snowflake
- Databricks
- BigQuery
- Redshift
- Azure Synapse
- PostgreSQL
- SAP S/4HANA
- Oracle Fusion
- Amazon S3
- Azure Blob
- Google Cloud
- SFTP
- Your CRM
- Documents
- External research and signals
The information they carry
- Sales — units, volume, value
- Price — regular and promotional
- Trade terms and deductions
- Distribution and coverage
- Cost of goods
- Promotions and mechanics
- Market class and hierarchy
- Accounts and activity
One governed model
Remove the friction. Make the decision.
We will run your own class, channel and trade terms in a working session, and you keep the analysis.